The PRES. of VistaGen Therapeutics is Exercising Options

By Carrie Williams

Today it was reported that the PRES. of VistaGen Therapeutics (VTGNResearch Report), Ralph Snodgrass, exercised options to buy 2,500 VTGN shares at $1.50 a share, for a total transaction value of $3,750. The options were close to expired and Ralph Snodgrass retained stocks.

Following this transaction Ralph Snodgrass’ holding in the company was increased by 4.15% to a total of $79.03K.

See today’s analyst top recommended stocks >>

The Company has a Price to Book ratio of 23.2816. Currently, VistaGen Therapeutics has an average volume of 263.7K.

Starting in May 2018, VTGN received 19 Buy ratings in a row.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.